Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis

Journal of Cellular Biochemistry

Volumn 112, Issue 2, 2011, Pages 463-475

  Ivanov, Vladimir N ^a   Partridge, Michael A ^a   Huang, Sarah X L ^a   Hei, Tom K ^a  

^a Columbia University ^*  (United States)

Author keywords

apoptosis; COX 2; melanoma; NF KB; STAT3; TRAIL

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ARSENITE SODIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MITOCHONDRIAL DNA; MONOCLONAL ANTIBODY; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NSC 74859; PROTEIN INHIBITOR; PROTEIN KINASE B; RESVERATROL; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; RNA INTERFERENCE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CYCLOOXYGENASE 2; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MELANOMA; NF-KAPPA B; OXYGEN CONSUMPTION; POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79251648307     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22934     Document Type: Article

References (59)

1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y,. 2004. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 24: 2783-2840.
2. Alexeyev MF, Ledoux SP, Wilson GL,. 2004. Mitochondrial DNA and aging. Clin Sci (Lond) 107: 355-364.
3. Amadori S, Fenaux P, Ludwig H, O'Dwyer M, Sanz M,. 2005. Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent. Curr Med Res Opin 21: 403-411.
4. Ashkenazi A, Holland P, Eckhardt SG,. 2008. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630.
5. Beal MF,. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36: 381-386.
6. Chin L, Garraway LA, Fisher DE,. 2006. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20: 2149-2182.
7. Costantini P, Jacotot E, Decaudin D, Kroemer G,. 2000. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92: 1042-1053.
8. Coussens LM, Werb Z,. 2002. Inflammation and cancer. Nature 420: 860-867.
9. Darnell JE, Jr., 2002. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749.
10. Dhawan P, Singh AB, Ellis DL, Richmond A,. 2002. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62: 7335-7342.
11. Fulda S, Debatin KM,. 2004. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-346.
12. Fulda S, Debatin KM,. 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811.
13. Fulda S, Galluzzi L, Kroemer G,. 2010. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464.
14. Gogas HJ, Kirkwood JM, Sondak VK,. 2007. Chemotherapy for metastatic melanoma: Time for a change? Cancer 109: 455-464.
15. Grivennikov S, Karin M,. 2008. Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell 13: 7-9.
16. Hersey P, Zhuang L, Zhang XD,. 2006. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251: 131-158.
17. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C,. 2008. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128: 1499-1505.
18. Ivanov VN, Hei TK,. 2004. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem 279: 22747-22758.
19. Ivanov VN, Hei TK,. 2005. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: A role of suppression of the PI3K-AKT pathway. Oncogene 24: 616-626.
20. Ivanov VN, Hei TK,. 2006a. Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res 312: 1401-1417.
21. Ivanov VN, Hei TK,. 2006b. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res 312: 4120-4138.
22. Ivanov VN, Kehrl JH, Ronai Z,. 2000. Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene 19: 933-942.
23. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, Horvath CM, Ronai Z,. 2001. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7: 517-528.
24. Ivanov VN, Bhoumik A, Ronai Z,. 2003. Death receptors and melanoma resistance to apoptosis. Oncogene 22: 3152-3161.
25. Ivanov VN, Zhou H, Hei TK,. 2007. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 67: 5397-5407.
26. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK,. 2008. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314: 1163-1176.
27. Ivanov VN, Zhou H, Partridge MA, Hei TK,. 2009. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res 69: 3510-3519.
28. Jones RG, Thompson CB,. 2009. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23: 537-548.
29. Kanekura T, Goorha S, Kirtikara K, Ballou LR,. 2002. The involvement of NF-kappaB in the constitutive overexpression of cyclooxygenase-2 in cyclooxygenase-1 null cells. Biochim Biophys Acta 1542: 14-22.
30. Karin M,. 2009. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1: a000141.
31. Karin M, Lawrence T, Nizet V,. 2006. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
32. Kimmelman AC, Osada M, Chan AM,. 2000. R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene 19: 2014-2022.
33. Krasilnikov M, Ivanov VN, Dong J, Ronai Z,. 2003. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: Implications towards sensitization to apoptosis. Oncogene 22: 4092-4101.
34. Kreuz S, Siegmund D, Scheurich P, Wajant H,. 2001. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21: 3964-3973.
35. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K,. 2007. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 47: 546-555.
36. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, Sakamaki T, Pestell R, Bromberg J,. 2006. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66: 2544-2552.
37. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR,. 2009. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28: 961-972.
38. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY,. 2006. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 66: 11115-11119.
39. Lo HW, Cao X, Zhu H, Ali-Osman F,. 2010. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 8: 232-245.
40. Luo JL, Kamata H, Karin M,. 2005. IKK/NF-kappaB signaling: Balancing life and deathâA new approach to cancer therapy. J Clin Invest 115: 2625-2632.
41. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B,. 2003. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102: 1028-1034.
42. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M,. 1994. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56: 853-857.
43. Partridge MA, Huang SX, Hernandez-Rosa E, Davidson MM, Hei TK,. 2007. Arsenic induced mitochondrial DNA damage and altered mitochondrial oxidative function: Implications for genotoxic mechanisms in mammalian cells. Cancer Res 67: 5239-5247.
44. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P,. 2006. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175: 913-923.
45. Peng HH, Liang S, Henderson AJ, Dong C,. 2007. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 313: 551-559.
46. Perlis C, Herlyn M,. 2004. Recent advances in melanoma biology. Oncologist 9: 182-187.
47. Rigel DS,. 2002. The effect of sunscreen on melanoma risk. Dermatol Clin 20: 601-606.
48. Rigel DS, Friedman RJ, Kopf AW,. 1996. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 34: 839-847.
49. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M,. 1997. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7 (Suppl 2): S35-S42.
50. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M,. 2003. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759.
51. Schaefer U, Voloshanenko O, Willen D, Walczak H,. 2007. TRAIL: A multifunctional cytokine. Front Biosci 12: 3813-3824.
52. Soengas MS, Lowe SW,. 2003. Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
53. Subbaramaiah K, Dannenberg AJ,. 2003. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102.
54. Wu H, Goel V, Haluska FG,. 2003. PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122.
55. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A,. 2006. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12: 950-960.
56. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR,. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21: 1396-1408.
57. Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A,. 2009. Molecular determinants of melanoma malignancy: Selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther 8: 636-647.
58. Yu H, Pardoll D, Jove R,. 2009. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9: 798-809.
59. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE,. 2007. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13: 2422-2428.